LIGHT fused to a vascular targeting peptide has been found to normalize tumor blood vessels, activate CD4+/CD8+ T cells, and triggers TLS formation in immunotherapy-resistant pancreatic adenocarcinoma (64). Here, CD8A is linked to neoplasm.